Literature DB >> 2052698

Abnormal corpus callosum: a sensitive and specific indicator of multiple sclerosis.

A D Gean-Marton1, L G Vezina, K I Marton, G K Stimac, R G Peyster, J M Taveras, K R Davis.   

Abstract

The authors investigated whether identification of corpus callosal (CC) involvement might increase the specificity of magnetic resonance (MR) imaging in differentiating multiple sclerosis (MS) from other periventricular white matter diseases (PWDs). They prospectively evaluated 42 patients with MS and 127 control patients with other PWDs. Ninety-three percent of the MS patients demonstrated confluent and/or focal lesions involving the callosal-septal interface (CSI). These lesions characteristically involved the inferior aspect of the callosum and radiated from the ventricular surface into the overlying callosum. CSI lesions were optimally demonstrated on sagittal long repetition time (TR)/short echo time (TE) images and frequently (45% of cases) went undetected on axial images. Only 2.4% of the control patients had lesions of the CC. The authors conclude that midsagittal long TR/short TE images are highly sensitive and specific for MS and that callosal involvement in MS is more common than previously reported.

Entities:  

Mesh:

Year:  1991        PMID: 2052698     DOI: 10.1148/radiology.180.1.2052698

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  36 in total

1.  Conduction deficits of callosal fibres in early multiple sclerosis.

Authors:  K Schmierer; L Niehaus; S Röricht; B U Meyer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

2.  Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication.

Authors:  Andrew J Steelman; Jeffrey P Thompson; Jianrong Li
Journal:  Neurosci Res       Date:  2011-10-12       Impact factor: 3.304

3.  Diffusion tensor group tractography of the corpus callosum in clinically isolated syndrome.

Authors:  F Lin; C Yu; Y Liu; K Li; H Lei
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-21       Impact factor: 3.825

4.  The ependymal "Dot-Dash" sign: an MR imaging finding of early multiple sclerosis.

Authors:  Christopher J Lisanti; Patrick Asbach; William G Bradley
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

Review 5.  Acquired lesions of the corpus callosum: MR imaging.

Authors:  A Uchino; Y Takase; K Nomiyama; R Egashira; S Kudo
Journal:  Eur Radiol       Date:  2005-11-12       Impact factor: 5.315

6.  Age-related signal intensity changes in the corpus callosum: assessment with three orthogonal FLAIR images.

Authors:  Akira Yamamoto; Yukio Miki; Hidekazu Tomimoto; Mitsunori Kanagaki; Takahiro Takahashi; Yasutaka Fushimi; Junya Konishi; Tabassum Laz Haque; Kaori Togashi
Journal:  Eur Radiol       Date:  2005-04-26       Impact factor: 5.315

7.  Enhanced corticomotor excitability with dynamic fatiguing exercise of the lower limb in multiple sclerosis.

Authors:  Gary W Thickbroom; Paul Sacco; Deborah L Faulkner; Allan G Kermode; Frank L Mastaglia
Journal:  J Neurol       Date:  2008-03-14       Impact factor: 4.849

Review 8.  [Corpus callosum. Landmark of the origin of cerebral diseases].

Authors:  E Hattingen; M Nichtweiss; S Blasel; F E Zanella; S Weidauer
Journal:  Radiologe       Date:  2010-02       Impact factor: 0.635

9.  Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study.

Authors:  F J Barkhof; M Elton; J Lindeboom; M W Tas; W F Schmidt; O R Hommes; C H Polman; A Kok; J Valk
Journal:  J Neurol       Date:  1998-03       Impact factor: 4.849

10.  Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome.

Authors:  Jan Dörr; Helena Radbruch; Markus Bock; Jens Wuerfel; Anne Brüggemann; Klaus P Wandinger; Daniel Zeise; Caspar F Pfueller; Frauke Zipp; Friedemann Paul
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.